Glenmark Pharmaceuticals witnessed a sharp decline in its stock price after the US Food and Drug Administration (FDA) issued a product recall that shook investor confidence. The pharmaceutical major saw its shares tumble by nearly 7% on Wednesday, April 9, following reports of a Class-II recall involving 39 of its drug products shipped to the …